Functional modeling of the ACVR1 (R206H) mutation in FOP

Clinical Orthopaedics and Related Research

Volumn 462, Issue , 2007, Pages 87-92

  Groppe, Jay C ^a   Shore, Eileen M ^b   Kaplan, Frederick S ^b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; ACVR1 PROTEIN, HUMAN; ARGININE; HISTIDINE; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL PH; COMPUTER MODEL; CRYSTAL STRUCTURE; GENE MUTATION; OSSIFYING MYOSITIS; PRIORITY JOURNAL; WILD TYPE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; POINT MUTATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

ACTIVIN RECEPTORS, TYPE I; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARGININE; COMPUTER SIMULATION; HISTIDINE; HUMANS; MODELS, GENETIC; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MYOSITIS OSSIFICANS; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 34548457296     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e318126c049     Document Type: Article

References (22)

1. Ahn J. Serrano de la Pena L, Shore EM, Kaplan FS. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am. 2003;85:667-674.
2. de la Pena LS, Billings PC, Fiori JL, Ahn J, Kaplan FS, Shore EM. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res. 2005;20:1168-1176.
3. Fiori JL, Billings PC, de la Pena LS, Kaplan FS, Shore EM. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2006;21:902-909.
4. Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-β type I receptor inhibitor. J Med Chem. 2006;49:2210-2221.
5. Glaser DL, Kaplan FS. Treatment considerations for the management of Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3:243-250.
6. Huse M, Chen YG, Massagué J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell. 1999;96:425-436.
7. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J. The TGF-β receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell. 2001;8:671-682.
8. Kaplan FS, Glaser DL. Thoracic insufficiency syndrome in patients with Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3:213-216.
9. Kaplan FS, Glaser DL, Shore EM, Deirmengian GK, Gupta R, Delai P, Morhart R, Smith R, Le Merrer M, Rogers JG, Connor JM, Kitterman JA. The phenotype of Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3:183-188.
10. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in Fibrodysplasia Ossificans Progressiva. Pediatrics. 2005;116:654-661.
11. Lehmann K, Seemann P, Stricker S, Sammar M, Meyer B, Suring K, Majewski F, Tinschert S, Grzeschik KH, Muller D, Knaus P, Nurnberg P, Mundlos S. Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2. Proc Natl Acad Sci USA. 2003;100:12277-12282.
12. Perutz MF, Muirhead H, Mazzarella L, Crowther RA, Greer J, Kilmartin JV. Identification of residues responsible for the alkaline Bohr effect in haemoglobin. Nature. 1969;222:1240-1243.
13. Pignolo RJ, Suda RK, Kaplan FS. The Fibrodysplasia Ossificans Progressiva Lesion. Clin Rev Bone Miner Metab. 2005;3:195-200.
14. Rötzschke O, Lau JM, Hofstatter M, Falk K, Strominger JL. A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules. Proc Natl Acad Sci USA. 2002;99:16946-16950.
15. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem. 2003;46:3953-3956.
16. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorg Med Chem Lett. 2004;14:3581-3584.
17. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, Kaplan FS. Overexpression of an osteogenic morphogen in Fibrodysplasia Ossificans Progressiva. N Engl J Med. 1996;335:555-561.
18. Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of Fibrodysplasia Ossificans Progressiva. Clin Rev Bone Miner Metab. 2005;3:201-204.
19. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525-527.
20. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg Med Chem Lett. 2003;13:4355-4359.
21. Weiser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995;14:2199-2208.
22. Yi SE, Daluiski A, Pederson R, Rosen V, Lyons KM. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development. 2000;127:621-630.